Leukemia is a cancer of the blood or bone marrow characterized by an abnormal increase of immature white blood cells. There are several types classified by how quickly the disease develops (acute or chronic) and the affected blood cell type (lymphoid or myeloid). Common types include acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia. Treatment involves chemotherapy, radiation therapy, or stem cell transplantation and varies depending on the leukemia type and stage.
complete information about the cancer condition that is leukemia - introduction, definition, etiology and causes, pathophysiology ,types, clinical manifestations, diagnosis, nursing management, medical management, nursing research .
my reference
Clinical pharmacy and therapeutics, Roger Walker
Rang & Dale’s pharmacology
Essential of medical pharmacology, K D Tripathi
www.google.com
A brief presentation on the topic "Leukemia" from a scientific perspective, providing details about risk factors, classifications, Types, treatment, symptoms, diagnosis & risk data with it's concerned resource mentioned.
Acute lymphocytic leukemia (ALL) occurs primarily in children. Leukemia Cancer doctor In Delhi NCR counts about 6,000 new cases of ALL are diagnosed yearly. The 5-year’s survival rate is 69.9 percent.
visit our website to get appointment with best Cancer Doctor in Delhi NCR : https://cancerconsultindia.com/
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
2. Definition
Leukemia is a type of cancer of the blood or bone
marrow characterized by an abnormal increase of
immature white blood cells called "blasts".
Leukemia is a broad term covering a spectrum of
diseases. In turn, it is part of the even broader group
of diseases affecting the blood, bone marrow, and
lymphoid system, which are all known as tumors of
the hematopoietic and lymphoid tissues.
Leukemia is a treatable disease. Most treatments
involve chemotherapy, medical radiation therapy, or
hormone treatments.
3. Classification
There are several types of leukemia. The different types
of leukemia are grouped in two ways. One way is by how
quickly the disease develops and gets worse. The other
way is by the type of blood cell that is affected.
By how quickly the disease develops
• Chronic
• Acute
By the type of blood cell that is affected
• Lymphoid cells
• Myeloid cells
4. Types
I. Acute lymphoblastic leukemia (ALL)
II. Acute myeloid leukemia (AML)
III.Chronic lymphoblastic leukemia(CLL)
IV.Chronic myeloid leukemia (CML)
Other types
• Hairy cell leukemia (HCL)-
• T-cell prolymphotic leukemia (T-PLL)-
• Larger granular lymphocytic leukemia – T-cell or NK cell
• Adult T-cell leukemia – C/A Human T-lymphotropic virus
(HTLV)
5. Pre –leukemia
Transient myeloproliferative disease, also termed
transient leukemia, involves the abnormal proliferation
of clone of non-cancerous megakaryoblasts.
The disease is restricted to individuals with down
syndrome .
Resolves within 3 months or ,in 10 % of cases ,progresses
to acute megakaryoblastic leukemia .
11. • Abnormal bone marrow
- AML
-ALL
-CML
-CLL
- Myeloproliferative disorders
12. Leukemia V/S Lymphoma
• Malignant cells diffusely
invade the bone marrow
and get spilled into the
peripheral circulation
• Peripheral blood film can
be diagnostic
• Bone marrow is almost
always involved
• Malignant cells form a
soft tissue mass in some
tissues or organs
• Do not spill into
peripheral blood
• Peripheral blood film is
often not diagnostic
• Bone marrow is not
always involved
• Biopsy of the mass is
often needed for
diagnosis
13. Acute V/S Chronic leukemia
• Leukemia may be acute or chronic
• Acute leukemia are more aggressive and the
patient may die in few months
• Chronic leukemia have more indolent course
of many years
14. Causes of leukemia
The aetiology of Leukaemia is not known in most patients. However,
a number of factors have been implicated.
1. Genetic factor:
There is high concordance rate among identical twins if acute leukaemia
develops in the first year of life. Families with excessive incidence of
leukaemia have been identified. Acute leukaemia occur with increased
frequency with a variety of congenital disorder such as Down‟s, Bloom‟s,
Klinefelter‟s and WiskottAldrich‟s syndrome, Fanconi„s anaemia and ataxia
telangiectsia.
2. Environmental factors:
Certain environmental factors are known to play a role in the aetiology of
leukaemia. These include the following;
a. Ionising radiation-e.g.-in individuals exposed to occupational radiation
exposure, patients receiving radiation therapy, and Japanese survivors of
the atomic bomb explosions. Radiation exposure is related to the
development of CML, AML and all but not to CLL or HCL.
b. Chemical carcinogens-e.g. Benzene and other aromatic hydrocarbons
are associated with the development of AML.
15. 3. Infection- Induction of Leukaemia‟s in experimental animals by RNA viruses
(retro viruses) has been studied for quite some time but more recently viral
aetiology of adult T-cells Leukaemia –Lymphoma (ATLL) by a human retro virus
called human T cells leukaemia –lymphoma virus I (HTLV-I) and (HTLV-II) for T
cells variant of hairy cells leukaemia has been established
4. Cigarette, cigar, and pipe smoking have been associated with cancers of the
lung, mouth, bladder, colon, kidney, throat, nasal cavity, voice box,
oesophagus, lip, stomach, cervix, liver, and pancreas, and with leukemia
16.
17. Acute leukemia
• Increased proliferation of immature cells
(blast cells)
• Only proliferation but no maturation or
differentiation
• Functionless blast cells accumulate in bone
marrow and finally spills into the peripheral
circulation
• No space for normal cells in bone marrow
• Decreased normal functional cells
18. Acute lymphocytic leukemia
ALL is the most common type of leukemia in young
children. It also affects adults, especially those 65 and
older.
Subtypes include precursor B acute
lymphoblastic leukemia, precursor T acute
lymphoblastic leukemia, Burkitt's leukemia,
and acute biphenotypic leukemia.
While most cases of ALL occur in children, 80% of
deaths from ALL occur in adults
19. Treatment of ALL
Management of ALL is directed towards control of bone marrow and systemic
(whole-body) disease. Additionally, treatment must prevent leukemic cells from
spreading to other sites, particularly the central nervous system (CNS) e.g.
monthly lumbar punctures. In general, ALL treatment is divided into several
phases:
Induction chemotherapy to bring about bone marrow remission. For adults,
standard induction plans include prednisone, vincristine, and
an anthracycline drug; other drug plans may include L-
asparaginase or cyclophosphamide. For children with low-risk ALL, standard
therapy usually consists of three drugs (prednisone, L-asparaginase, and
vincristine) for the first month of treatment.
Consolidation therapy or intensification therapy to eliminate any remaining
leukemia cells. There are many different approaches to consolidation, but it is
typically a high-dose, multi-drug treatment that is undertaken for a few months.
People with low- to average-risk ALL receive therapy with antimetabolite drugs
such as methotrexateand 6-mercaptopurine (6-MP). People who are high-risk
receive higher drug doses of these drugs, plus additional drugs.
]
20. CNS prophylaxis (preventive therapy) to stop the cancer from
spreading to the brain and nervous system in high-risk people.
Standard prophylaxis may include radiation of the head and/or
drugs delivered directly into the spine.
Maintenance treatments with chemotherapeutic drugs to prevent
disease recurrence once remission has been achieved.
Maintenance therapy usually involves lower drug doses, and may
continue for up to three years.
Alternatively, allogeneic bone marrow transplantation may be
appropriate for high-risk or relapsed people.
21. Acute myeloid leukemia
(AML) occurs far more commonly in adults than in children, and
more commonly in men than women. It is treated with
chemotherapy. The five-year survival rate is 20%.
One subtype is APL (Acute Promyelocytic Leukemia), which has a
survival rate greater than 90%. Subtypes of AML include acute
promyelocytic leukemia, acute myeloblastic leukemia, and acute
megakaryoblastic leukemia.
22. Treatment of AML
Many different anti-cancer drugs are effective for the treatment of
AML. Treatments vary somewhat according to the age of the person
and according to the specific subtype of AML. Overall, the strategy is
to control bone marrow and systemic (whole-body) disease, while
offering specific treatment for the central nervous system (CNS), if
involved.
In general, most oncologists rely on combinations of drugs for the
initial, induction phase of chemotherapy. Such combination
chemotherapy usually offers the benefits of early remission and a
lower risk of disease resistance.
Consolidation and maintenance treatments are intended to prevent
disease recurrence. Consolidation treatment often entails a repetition
of induction chemotherapy or the intensification chemotherapy with
additional drugs. By contrast, maintenance treatment involves drug
doses that are lower than those administered during the induction
phase
25. Chronic Myeloid Leukemia
• Clonal Myeloproliferative disorder
• Incidence is 1.5 per 100,000 people per year
• Constitute about 20% of all leukemia
• Male > Female
• Increases slowly with age until the middle
forties, when it starts to rise rapidly
• The median age of diagnosis is 45 to 55 years
• No etiologic agent is incriminated in CML
26. Chronic Myeloid Leukemia
• CML is a/w Philadelphia
chromosome
• The Ph chromosome is an
abnormal chromosome
22, resulting from a
reciprocal translocation
between part of the long
arm of chromosome 22
and chromosome 9.
• The resulting karyotype is
described as
t(9;22)(q34;q11)
27. Chronic Myeloid Leukemia
• This translocation
results in fusion of
Break point cluster
region (BCR) gene of
Chr 22 with Abelson
1(Abl) gene of Chr 9
resulting in Ongogenic
BCR-Abl fusion gene
located in Ph
chromosome
28. Chronic Myeloid Leukemia
• The new BCR-Abl fusion gene is capable of
being expressed as a messenger RNA &
encodes the Bcr-abl fusion protein.
• The translated p210 protein has tyrosine
kinase activity and enhanced phosphorylating
activity compared with the normal protein
resulting in altered cell growth, stromal
attachment and apoptosis ultimately leading
to CML
29. Clinical Presentations
• CML can present as one of the three phases
– Chronic Phase
– Accelerated Phase
– Blast Crisis
30. Clinical Presentations
• Asymptomatic to severely symptomatic
• Symptoms due to splenic enlargement
– Early satiety and left upper quadrant pain or mass
• Symptoms due to hypermetabolic state
– fatigue, malaise, weight loss, night sweats
• Symptoms due to leukostatic manifestations due to
severe leucocytosis
– CVA, MI, venous thrombosis, priapism, visual disturbances,
pulmonary insufficiency
• Less common are features related to granulocyte or
platelet dysfunction
– infections, thrombosis, or bleeding.
31. Clinical Presentations
• Physical findings
– Also depends upon the phase of CML
– Mild anemia to severe anemia
– Splenomegaly
– Hepatomegaly
– Lymphadenopathy unsual but can be present at
late stages (blast crisis)
– Bleeding disorders and Infections are rare unless
in blast crisis
32. Chronic Phase
• Majority of CML are diagnosed in chronic phase
• Defined by
– Elevated WBC >50,000 (10,000-5,00,000) with left
shift extending to blasts
– Blasts <10% in peripheral blood or bone marrow
– Thrombocytosis and increased Basophils, Eosinophils
– Mild normocytic normocromic anemia
– Low leucocyte alkaline phosphatase score
• Median duration is 4-5 years
33. Accelerated Phase
• Second and intermediate phase
• Defined by
– 10-20% blast cells blood or marrow
– basophils ≥20%, platelet count <100,000
– Progressive anemia
– General worsening of the symptoms
• Median duration is 3-18months
34. Blast Crisis
• Final phase of the disease
• Transformation into Acute leukemia with
blasts ≥ 20% (Myeloid 70% and lymphoid 30%)
• Increased symptomatology
– Fatigue due to severe anemia
– Bleeding, infections
– Lymphadenopathy
– CNS involvement
• Rapidly fatal
35. • Diagnosis of CML is not difficult
– Leucocytosis with left shifting extending to blasts
– Splenomegaly
– Presence of Philadelphia chromosome (90-95%) or
BCR-Abl mRNA in bone marrow sample or blood
36. Treatment of CML
• Treatment of chronic phase
– Tyrosine kinase inhibitors
– Allogenic stem cell transplantation
– Interferon alpha based treatment
– Chemotherapy to reduce WBC counts with
hydroxyurea or busulphan
37. • Tyrosine kinase inhibitors
– Imatinib ( 1st gen), Dasatinib, Nilotinib (newer gen)
– First-line therapy in chronic-phase CML
– Inhibit BCR-ABL tyrosine kinase activity and reduce the
uncontrolled proliferation of WBC
– Complete cytogenetic response is seen in 76% at 18
months of therapy
– Therapy is continued for life in those with complete
cytogenetic response
– Patients are monitored by repeated bone marrow
examination at 6, 12 and 18 months for complete
cytogenetic response then 3-monthly real-time
quantitative polymerase chain reaction (PCR) for BCR ABL
mRNA transcripts in blood.
38. • Tyrosine kinase inhibitors
– Those who don’t obtain complete cytogenetic
response at 18 months of treatment are labeled as
treatment failure with imatinib
– These pts are treated with either newer
generation TKIs (desatinib, nilotinib) or allogenic
stem cell transplantation
39. • Allogenic stem cell transplantation
– Reserved for treatment failure patients with
imatinib
• Interferon alpha with cytarabine, hydroxyurea
or busulphan are being obsolete
• `3
40. Treatment of CML
• Treatment of accelerated phase
– Imatinib is indicated if the patient has not already
received it but the response is poor
– Hydroxyurea can be used as palliative therapy
41. Treatment of CML
• Treatment of blast crisis
– Type of blast should be determined and treated as
acute leukemia
– Lymphoblastic transformation is better treated
than myeloblastic
– Supportive management should be considered in
very old pts with myeloid transformation due to
very poor response to treatment
43. CLL
• Most common type of leukemia
• Male to female ratio is 2 : 1
• Median age at presentation is 65–70 years
• It results from the clonal expansion of small
lymphocytes and is almost invariably (95%) B cell in
origin
• B lymphocytes fail to transform to plasma cells or
produce antibodies
• An ever-increasing mass of immuno-incompetent cells
accumulates resulting in decrease immunity and bone
marrow failure
44. Clinical features of CLL
• The onset is usually insidious.
• In most cases the diagnosis is made incidentally
on a routine CBC.
• In the late stages the patient may present with
features of
– Bone marrow failure,
– Anemia due to autoimmune hemolysis,
– Increased susceptibility to infection,
– Painless lymphadenopathy and
– Systemic symptoms like night sweats and weight loss.
45. Investigations
• CBC
– WBC is increased with lymphocytosis ( > 5 X 109/L is
criteria for diagnosis)
– RBC may be normal or decreased
– Plts may be normal or decreased
• Peripheral blood smear
– Small or medium sized mature and normal appearing
lymphocytes.
– Smudge cells may be seen
– No immature blasts are evident.
46. Investigations
• Immunophenotyping
– Monoclonal B cells expressing the B cell antigens
CD19 and CD23, with either kappa or lambda
immunoglobulin light chains
• Serum immunoglobulin
– levels should be estimated to establish the degree
of immunosuppression
47. Investigations
• Bone marrow examination
– Not essential for the diagnosis of CLL
– For prognosis (patients with diffuse marrow
involvement have a poor prognosis)
– Monitoring treatment
• Other
– Retics
– Direct Coomb’s test
49. Treatment
• Treatment is only required if
– there is evidence of bone marrow failure
– massive or progressive lymphadenopathy or
splenomegaly
– systemic symptoms such as weight loss or night
sweats
– rapidly increasing lymphocyte count
– autoimmune haemolytic anaemia
– thrombocytopenia
50. Treatment
• Stage A CLL
– No treatment is needed apart from the proper
counselling about the disease
51. Treatment
• Stage B and C CLL
– Oral chemotherapy with chlorambucil
– Purine analogue fludarabine in combination with
cyclophosphamide
– Anti-CD20 monoclonal antibody rituximab
– Corticosteroids for autoimmune cytopenias
52. Treatment
• Supportive treatment
– Transfusions of blood for symptomatic anaemia or
thrombocytopenia
– prompt treatment of infections or
immunoglobulin replacement.
– Radiotherapy for lymphadenopathy which is
causing discomfort or local obstruction
– Splenectomy
53. Prognosis
• The success of treatment depends on the type of leukemia and the age of
the person. Outcomes have improved in the developed world.
• The average five-year survival rate is 61% in the United States. In children
under 15, the five-year survival rate is greater (60 to 85%), depending on
the type of leukemia. In children with acute leukemia who are cancer-free
after five years, the cancer is unlikely to return.
• Outcomes depend on whether it is acute or chronic, the specific abnormal
white blood cell type, the presence and severity
of anemia or thrombocytopenia, the degree of tissue abnormality, the
presence of metastasis and lymph node and bone marrow infiltration, the
availability of therapies and the skills of the health care team.
• Treatment outcomes may be better when people are treated at larger
centers with greater experience
55. Raktarbud
According to vagbhat, Vitiated Dosha will constricted and compress the blood
within the Venous (siras). This will be mature it before time hence obstruction of
bleeded blood produce lump of mamsa covered with muscular sprouts and grow
very fast along with bleedings. This vitiated Shonit (blood) along with circulating
blood within vessels produced Blood cancer. This make the patients suffer from
pandu (Anaemia) and complication of blood
Cancer originates due to a metabolic crisis, i.e. aggravation of vata forces and
suppression of kapha forces, both interacting with one another resulting in
proliferation. However, the abnormal cancerous growth at a specific organ
(Ekadesavriddhi) is managed by compensation from other parts of the body
(Anyasthaniyakshaya), e.g. body weight loss (cachexia) .
Sushruta has proposed six stages in the pathogenesis of all diseases but his
concept suits more to the pathology of the tumour than pathogenesis itself.
56. Stages of tumour according to Ayurveda
1. Sanchaya: early stages of localized neoplastic changes.
2. Prakopa: transformation of primary growths into metastatic tumours.
3. Prasara: metastasis.
4. Sthana samsraya: complete metastasis and secondary growth.
5. Vyakti: clinical signs and symptoms are expressed.
6. Bheda: the stage where differentiation of growth occurs on the basis of
histopathology
57. Treatment modalities in Raktarbud
During the 7th century BC, Atreya and Dhanwantari used ayuveda medicines for
treating the early stages of cancer and surgery in advanced cases.
In the 8th century AD, Vagbhata, a Buddhist physician composed two texts:
Astanga Hrdaya and Astanga sangraha where new methods for cancer treatment
were introduced.
Other Ayurvedic texts of internal medicine, viz., Chakradatta composed by
Chakrapani (10th century AD), the Sarangadhara Samhita by Sarangadhara (14th
century AD), the Bhavaprakasha Samhita by Bhavamisra (15th century AD), the
Satmya Darpan Samhita by Viswanath (16th century AD), the Vaisajya Ratnabali
by Binoda Lala Sen Gupta (18th Century AD), the Rasatarangini by Sadananda
Sharma (19th century AD), etc. explain numerous remedies to treat internal and
external neoplasms.
58. Treatment modalities
Though there is no basic line of treatment of Leukaemia has found in Ayurveda, as
it is Asadhya (incurable), but principle of treatment is as follows :
• Sodhana chikitsha
• Saman chikitsha
• Rasayan chikitsha
• Dhatwagni chikitsha
• Vyadhipratyanika chikitsa (specific anti-cancerous drugs)
• Lakshanika chikitsa (symptomatic treatment)
59. Herbs used in leukemia
Sandpushpa juice (10-20ml) and paste (10gm) of whole plant, leaf
and root will be useful to cured Leukaemia.
Bhallatak will be cutted and boil in 200 ml milk after then it will be
keeping for cool automatically and then ingested orally after
application of Dharat in to mouth.
Vanpalandu tuber churna(120-200mg), syrup(30-60 ml) and
tincture (5-30) drop will be useful in curing Leukaemia.
Vantrapush root churn (250-500mg) and root abstract (15-60mg)
will be useful in curing Leukaemia.
Gugulunirayas(2-4gm) will be useful to cure Leukaemia.
1. A.charyap. Sharma, hindi commentary, Drayva Guna Vigyan. Vol (II), Chaukhamba Bharti Academy Varanasi, Reprint edition-2009; 832.
2. Acharyap. Sharma, hindi commentary, Drayva Guna Vigyan. Vol (II), Chaukhamba Bharti Academy Varanasi, Reprint edition- 2009;
168-169.
3. Acharyap. Sharma, hindi commentary, Drayva Guna Vigyan. Vol (II), Reprint edition Chaukhamba Bharti Academy Varanasi, Reprint
edition- 2009; 207.
4. Acharyap. Sharma, hindi commentary, Drayva Guna Vigyan. Vol (II), Chaukhamba Bharti Academy Varanasi, Reprint edition- 2009; 834.
5. . Ambikadatt Shastri, hindi commentary, Susuhrut Samhita. Chikitsha Sthan 5/ 40-45, Chaukhambha Publication Varanasi, Reprint
edition- 2011; 45.
60. Polyherbal and herbomineral compound used in Raktarbud
• Rodhra ras
• Vradha dharu
• Vradhadaru yoga
• Nityanada ras
• Kanchanar gugulu
• Hargauri ras
There are also clinical researches of certain Ayurvedic herbs and a mineral on
Leukaemia has published recently:
1. Navjeevan Ras
2.Kamdudha Ras
3.Keharubapisti having content Trinakantamanichurn, Gulab ark (for mardan)
4. Semicarpusana cardium has resulted in significant clearance of the leukemic cells from the bone marrow
and internal organs in Leukaemia animals with compare standreddrug imatinib mesylate. [4]
5. Semi synthetic anti cancerous drug of Podophyllum hexandrrum and lead compound namely etoposide,
teniposide, etopophes, which are used for the treatment of cancer including Leukaemia.[5,6]
6. Gugulipid mediated suppression of cancer cell proliferation reported significant in Leukaemia cell.[7,8]
1. http://www.jaim.in. [IP: 117.239.29.130]
2. http://www.jaim.in. [IP: 117.239.29.130]
3. http://www.jaim.in., [IP: 117.239.29.130]
61. 4. P.K. Raveedran Nair et.al, Isolation and characterization of an anticancer catechol compound from
Semecarpusana cardium. Journal of Ethnopharmacology journal,2009;1-7
5. Imbert Tf, Discovery of Podophyllotoxin, Biochimie, 80 (1998); 207-222.
6. Stahelin HF & Wartburg VA, The chemical and biological route from Podophyllotoxinglucoside to etoposide:
Ninth cain memorial award lecture, cancer Res, 51 (1991);5-15.
7. Samudio I, Konopleva M, Safe S, McQueen T, Andreeff M () Guggulsterone induce apoptosis and
differentiation in acute myeloid leukemia: identification of isomer-specific antileukemic activities of the
pregnadienedione structure. Mol Cancer Ther2005, Vol.4; 1982-1992.
8. Shishodia S, Aggarwal BB Guggulsterone inhibits NF-kappaB and Ikappa Balpha kinase activation, suppresses
expression of anti-apoptotic gene products, and enhances apoptosis. J BiolChem2004, 279 (4); 7148-4715